Keywords: Daiichi Sankyo, ArQule, ARG 092, Lung cancer, NSCLC

Daiichi Sankyo to license ARQ 092 from ArQule, under joint AKIP research collaboration

Article | 11 November 2011

Print This

Japanese drug major Daiichi Sankyo (TSE 4568) says it has executed a license agreement with USA-based ArQule (Nasdaq: ARQ) for the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in